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Introduction
The dorsal root ganglia (DRG) is a primary sensory tissue in vertebrate nervous systems, delivering sensory signals from the body to the central nervous system (CNS) via pseudounipolar neurons. The DRG is composed of several specialized cell types including proprioceptive, lowthreshold and damage-sensing nociceptive sensory neurons (nociceptors) as well as Schwann cells, fibroblasts and satellite glial cells (SGCs). With the advent of high-throughput RNA-seq, there has been a concerted effort on generating whole transcriptome snapshots of DRG and other tissues with recent emphasis on single cell RNA-seq (scRNA-seq) studies. Thus far, efforts have largely been directed toward mouse DRG (mDRG) [54] and rat DRG [46] , with some focusing on single neuron [14; 51; 107] or specific neuronal subpopulations [29; 37; 102] highlighting nociceptors. Such studies are informative because they focus on profiling a key neuronal subpopulation in the context of detecting nociceptive signals and generation of pain, enhancing our understanding of the molecular biology and diversity of these neurons. The hDRG in general, and nociceptors in particular, are widely viewed as tissue and cell types with possibilities for discovering biological targets for analgesic drugs, leading to development of therapeutics for both acute and chronic pain [66; 92] that do not involve the CNS and avoid resulting complications [4; 19] . Studies identifying transcriptional [20; 32; 116; 119] (including scRNA-seq efforts [35] ) and proteomic [89] changes in preclinical pain models have been undertaken, but do not account for evolutionary differences in DRG transcriptomes between rodent models and humans. Such preclinical models can potentially suffer from translational issues as they move toward the clinic [94] . Studies characterizing transcriptome profiles of human nociceptors and DRG (or related tissues and cell types in vivo or in vitro) present opportunities for advancing understanding of basic pain mechanisms and therapeutic targets but a limited number of such in vitro [111] or in vivo [25; 91; 98; 111] studies have been performed. The SymAtlas [98] project provided the first in vivo, high-throughput (but incomplete) characterization of the hDRG transcriptome using microarrays. Recent in vivo studies [25; 91] perform RNA-seq, but have mainly focused on specific gene families or diseases, without systematic comparison with preclinical models.
We performed RNA-seq on female, human organ donor L2 DRG tissues. Comprehensive analyses of the transcriptional landscape with respect to other human tissues identified gene coexpression modules and hDRG-enriched genes in pertinent gene families and signaling pathways. As a starting point for therapeutic target identification, we identified the set of genes with conserved DRG enrichment in human and mouse, and mined drug databases to catalog interactions of known drugs with products of these genes. This effort is the first to present whole transcriptome gene abundances for hDRGs and mDRGs, contrasted with relevant human and mouse tissues via our online repository (www.utdallas.edu/bbs/painneurosciencelab/DRGtranscriptome).
Methods
We performed RNA-seq for hDRG and integratively analyzed the transcriptome by comparing it with publicly available human and mouse RNA-seq datasets (sources shown in Table 1 , and the workflow for the project shown in Figure 1 ). We also used publicly available human microarray data to contrast whole human DRG and Trigeminal Ganglia (TG) (GEO PRJNA87249) [98] , along with two datasets representative of its component cell types: cultured primary Normal Human Schwann Cells (NHSCs) from peripheral nerves (GEO GSE14038) [62] and cultured fibroblasts (FIBRO) from the skin (GEO dataset GSE21899). We were unable to find a dataset for purified satellite glial cells (SGCs) in any database. We further integrated published quantification from mDRG scRNA-seq analyses [107] (lumbar DRG, GEO GSE59739) to putatively identify cell-type specific expression in DRG enriched genes. For ease of discourse, human gene names (in upper case) are used in the text to refer to both human genes and its orthologs, with the species being apparent from context. Mouse gene names and human protein names are capitalized, with human protein names being additionally italicized, when used in the paper. At the outset, it is important to clarify that our analyzed tissue panel only queries a finite set of adult, healthy tissue; and the notions of 'DRG enriched' and 'DRG specific' gene expression is with respect to this set of reference tissues that provide a relevant testbench for asking questions about mammalian DRG.
Human DRG preparation and RNA-seq
Tissue was sourced from Anabios, Inc (San Diego, CA). For this study, L2 lumbar DRGs were removed from 3 female consented organ donors prior to cross clamp and stored immediately in RNALater (Ambion, Austin, TX). RNA-seq was performed on the whole tissue by Active Motif, Inc (San Diego, CA). An RNEasy Qiagen kit was used for total RNA isolation, and DNA was removed using DNase-I digestion. The extracted total RNA was then used with an Illumina Truseq RNA sample preparation v2 kit to generate polyA+ RNA libraries for sequencing. 50 million paired-end 75 bp reads were sequenced from each sample on the Illumina platform. The RNA-seq datasets generated were contrasted with publicly available RNA-seq datasets in other relevant human tissues, and their orthologous tissues in the house mouse (M. musculus). For mDRG RNA-seq datasets, we used publicly available RNA-seq data from the C57BL/6 mouse strain, the inbred model strain used to sequence the reference mouse genome [13] .
Quantification of gene abundances from RNA-seq experimental data
Mapping of sequenced reads and quantification of gene abundances: Sequenced FASTQ files generated by our RNA-seq experiments or downloaded from public databases were mapped to the human and mouse reference transcriptome for the purposes of quantifying relative gene abundance.
Reference human (NCBI hg19) and mouse (NCBI mm10) genomes [21] , and reference human (Gencode v14) and mouse (Gencode vM4) transcriptomes [33] were used for mapping sequenced reads. The Tophat / Cufflinks pipeline was used for analyzing the RNA-seq datasets [105] . The Burroughs-Wheeler transform based RNA-seq mapping tool Tophat [104] (v2.0.13) was used for mapping the sequencing reads with the following command-line parameters: . The gene abundance quantification tool Cuffdiff [103] (v2.2.1) was used to estimate relative abundances of genes in the reference transcriptome with the following command-line parameters: . Relative abundances were calculated for genes with respect to the reference library, based on Gencode coding genes, lincRNAs, pseudogenes and other noncoding genes with evidence for polyA site or signal [121] . Absolute abundance quantification of genes or transcripts require calibrating RNA-seq based on exogenous spike-ins with known copy numbers [78] or other methods is rarely performed in practice, and typically require additional amounts of input material, or attachment of unique molecular barcodes to individual transcripts to correct amplification bias in traditional RNA-seq [96] , making them unfeasible or intractable for our samples with limited, varying amounts of tissue sourced from human donors.
Design decisions for RNA-seq analyses: While mapping RNA-seq datasets using Tophat, the number of mismatches allowed per alignment segment was set to the default (two), with all of our analyzed datasets, including the three hDRG samples we sequenced, having acceptable mapping rates for post-mortem samples (> 70%) [87] . For Tophat, all datasets were assumed to be generated from strand-agnostic libraries for the purposes of mapping. While some analyzed libraries were actually strand-specific, such an approach allows us to avoid the inherently different nature of strand specific and non-specific libraries, and minimizes the chances that downstream differential expression analysis will yield artifacts. Since the reference transcriptomes for human and mouse are well annotated by the GENCODE project, de novo assembly was not performed -instead, all concordantly mapped read pairs (fragments) mapping to each known transcript were used by Cuffdiff to quantify relative abundance. Finally, we additionally performed a second round of in silico library selection limiting analysis to only genes with known or predicted polyA+ transcripts (detailed in Section 2.3 under TPM calculations), to minimize the effect of whether total RNA or polyA+ selection was used for library construction in the different analyzed samples.
Sample statistics

Sample statistics for characterizing gene abundances in individual tissues for each species
The relative abundance of a transcript was calculated based on the number of frag We used upper quartile normalization to scale TPM measures such that the bimodal distribu relative abundances were comparable across both tissues and species. Based on the b empirical density functions of the uqTPMs in different tissues for both species, we categorized as ""expressed" versus "undetected or lowly expressed", when the mean abundance replicates was >= 0.75 uqTPM. Additionally, this allows for simplification of downstream analys coexpression module detection, identifying regulatory networks or gene set enrichment analysi
Sample statistics for characterizing tissue specificity of genes in individual species
A tissue-specific transcriptomic signature inevitably depends upon a set of tissue-res genes, potentially contributing to tissue-specific functionality or phenotype. The information th measure of Shannon's entropy [95] has been historically used in various domains as a framew assessing diversity in a population [34] , including the identification of tissue-restricted ge transcriptomics [117] . For each gene, the uqTPM levels were first normalized to 1, genera probability distribution with x i corresponding to the gene's normalized abundance corresponding to its uqTPM in the i th tissue. Based on this distribution, Shannon's entropy [95 was calculated to identify tissue-restricted genes that are expressed in the DRG :
Since the value of Shannon's entropy can vary between 0 and log 2 (n) where n = information (number of tissues in our case), we use Shannon's normalized measure of entropy which r between 0 (highest tissue specificity) and 1 (lowest tissue specificity):
We defined two additional formulations derived from this framework to characterize restricted genes of interest. We profiled nervous-system enriched genes among the set of restricted genes we characterized in this work, since these are potential targets or excluded t for drugs which do or do not cross the blood brain barrier (BBB). We calculated a neural prop score by summing the proportion P(x i ) calculated for Shannon's entropy across all neural tiss our tissue panel. We also calculated a score for DRG enrichment that would take into accou The degree of neural or DRG enrichment for a gene can thus be estimated by contrasting the enrichment score with the overall distribution of the score across all genes.
Sample statistics for characterizing conservation of gene expression patterns in human and mouse
Based on the Homologene database [27] , we identified orthology mappings between human and mouse genes, using the Homologene gene family IDs. Every individual human to mouse gene mapping was categorized as being part of a one-to-one, one-to-many, many-to-one, or many-to-many mapping between gene sets, based on the relative timing estimates for duplication and speciation events. Additionally, genes with no orthologs in the other species were categorized as one-to-none, many-to-none, none-to-one, or none-to-many mapping. We additionally curated the Homologene database to correct orthology relationships that were inconsistent with the literature, most notably the relationships in the MRGPR family. Ensembl Compara [109] gene trees were used to guide this process, and the final set of homology mappings used are presented beside abundance data for each gene in Sheet 1 of Supplementary Files 1 and 2. Correlational measures (Pearson Correlation Coefficient or PCC [81] ) previously used in the literature [90] were calculated between the gene expression (uqTPM) vectors of human genes and their mouse orthologs across corresponding tissues, for those human and mouse genes that have a one-to-one orthology mapping and show either human or mouse DRG enrichment. We analyzed the empirical distribution of the DRG enrichment scores to identify hDRG enriched and mDRG enriched genes (DRG enrichment score > 0.29 in at least one species, corresponding to inclusion of all genes where uqTPM is highest in DRG across tissues) for all human and mouse genes, and restricted this gene set to genes with high correlation (determined from empirical distribution of the PCC) between human and mouse tissue expression panels.
Similarity analysis of gene and tissue expression profiles to identify gene expression signatures
The microarray datasets used were variations of the Affymetrix HG-U133A, and for each chip, the tool Oligo was used for microarray probe normalization [9] , followed by quantile normalization across chips [8] . Averaging across replicates, a clear unimodal distribution for probe intensity was identified ( Supplementary Fig. 3 ) for classifying probesets as expressed or unexpressed. The normalized intensity values are tabulated in Supplementary File 3. Since culturing cells can alter gene expression profiles [123] , we ignore probesets that were not expressed in hDRG or TG and characterized which of the hDRG or TG expressed probesets were expressed in NHSCs or fibroblasts.
For RNA-seq, we analyzed only genes with polyA+ transcripts, and performing upper quartile normalization, we aimed to minimize the effect of technical variation in our data. Within human datasets, genes were analyzed for co-expression patterns across all analyzed tissues, to identify sets of genes with similar expression patterns and cluster them into "modules" [23] . We assigned each gene a digital "co-expression pattern", based on whether the uqTPM in each tissue was >= 0.75 or not. The most frequent gene co-expression patterns were identified, along with TFs and other relevant genes in each module. The genes in the corresponding modules were then hierarchically clustered [23] and the resulting dendrogram optimally leaf-ordered on the genes [6] to depict the gene expression patterns across the set of analyzed human tissues. This allowed us to visualize relevant co-expression patterns and putatively identify regulatory circuitry underlying such co-expression.
We also performed hierarchical clustering of all human and mouse tissue transcriptome profiles, restricted to the set of genes to those with one-to-one orthology between human and mouse based on our analysis [27] . For the hDRG and mDRGs, all 3 individual replicates were individually used instead of a single tissue profile to identify the sample-to-sample variation relative to observed tissueto-tissue variation. The set of genes used for this analysis was limited to genes with tissue-restricted expression in order to identify a clear tissue-specific gene signature [85] .
Functional enrichment analysis
We identified human and mouse genes with relevant functional gene ontology descriptions, based on the Gene Ontology (GO) database [15] . Wherever possible, the set of human genes were augmented using the HGNC database [30] . The gene sets used are noted in Supplementary File 4.
Functional enrichment analysis was then performed using Enrichr [11] , allowing for multiple testing correction, with the Reactome database [17] being used for pathway analysis. In order to identify all known drug -gene product interactions for genes present in the conserved DRG enriched gene set, the Drug -Gene Interaction Database (DGIdb) [110] was used. Protein-protein interaction (PPI)
were mined based on validated interactions of genes with relevant GO terms in the StringDB database [26] . The KEGG database and visualization tool [42] was used to analyze the neurotrophin signaling pathway, used with permission from Kanehisa Laboratories (Supplementary File 5).
In silico detection of mRNA axonal localization
We contrasted relative abundances of mRNAs in the hDRG from our own RNA-seq experiments to human tibial nerve (hTN) RNA-seq experiments from the GTex consortium [16] . Changes in gene expression between the hDRG and hTN can be brought about by region-specific gene expression in non-neuronal cells, subcellular localization in sensory neurons, variable composition of cell types between hDRG and hTN samples, differential expression between sensory (present in hDRG and hTN) and motor neurons (present only in hTN) or a combination of all of these. The hDRG : hTN fold change was calculated based on TPM values for all genes, and is presented in Sheet 1 of Supplementary File 2. We restricted our analysis to genes whose orthologs show differential expression amongst mDRG neuronal subpopulations, since such sensory neuronal subpopulation restricted expression typically involves neuron-specific expression [51] .
Results
We introduce an open-data, searchable website for our analyses allowing users to visualize gene expression profiles (http://www.utdallas.edu/bbs/painneurosciencelab/DRGtranscriptome) across orthologous human and mouse genes. For reproducibility, code for performing calculation of the data underlying the figures: uqTPMs, and sample statistics for characterizing tissue specificity and conservation of expression are available in Supplementary File 6, and on our website.
Comparison of hDRG whole transcriptome profile with other transcriptome profiles
From a transcriptional point of view, the hDRG is a highly heterogeneous conglomerate of cells with multiple types of sensory neurons, Schwann cells, satellite glial cells, fibroblasts, and resident macrophages [72] . In vivo studies of heterogeneous tissues like the hDRG or hTN pose a special challenge, since mRNA species may be expressed specifically in individual cell types or more generically. We estimated the degree of overlap between the whole DRG transcriptomic profiles and some of its non-neuronal constituent cell types. We looked at assembled microarray datasets for human DRG, TG and cultured normal human Schwann cells (NHSC) and skin fibroblasts (FIBRO) ( Fig. 2A ). We identified 12,422 probesets that show expression in hDRGs. Of these, 11,407 (94.6%) are shared with the human TG, reiterating the overall similarity of the two tissues. Interestingly, we found that approximately 70% (8,666 / 12,422) of the DRG-expressed probesets show co-expression in either the NHSC or fibroblast dataset or both. The remaining 30% of the DRG-expressed probesets were putatively due to expression restricted to sensory neurons or SGCs and included nociceptorenriched channels like SCN10A and SCN11A [107] , and nociceptor-enriched transcription factors like PRDM12 [12] which are well characterized in mammalian DRGs. Our analysis indicates that cDNA libraries constructed from whole hDRGs have a strong non-neuronal component. 1
To look at conservation of gene expression across tissues in humans and mice in a transcriptome-wide fashion, we performed hierarchical clustering of the RNA-seq transcriptomes ( Fig.   2B ). We find that for non-neural tissues, homologous human and mouse tissues cluster in pairs. The hDRG replicates, mDRG replicates and hTN sample also cluster together, showing a distinct PNS gene expression profile, and low sample-to-sample variation in our hDRG and mDRG samples. Our findings agree with meta-analyses that suggest distinct signatures for human sensory tissues and brain tissues [100] , and that inter-study distances among homologous tissue transcriptomes are typically less than intra-study distances between different tissues [99] . However, inside the CNS tissue cluster, we find that the human samples and mouse samples do not cluster according to brain regions, and we attribute this to well characterized evolutionary divergence of the CNS transcriptome in humans with respect to other primates and rodents [61; 76] rather than batch or laboratory effects as the subclusters are not determined by source laboratory of the samples. Preclinical rodent models have been shown to mimic human response in several domains [100] . Our analysis identifies a distinct, evolutionarily conserved tissue-specific signature for healthy human and mouse PNS tissues, opening the door to the follow up question of how faithfully rodent pain models correlate with human pain signatures at the molecular level.
Co-expression patterns and regulatory programs shaping the hDRG
Based on our binary co-expression pattern for each coding or non-coding human gene, we found that 22,140 genes were expressed in one or more tissues, with 12,462 genes being generically expressed across the reference tissue panel based on their entropy ( Fig.s 3A and 3B ). Of the remaining 9,498 genes, we found a power law-like distribution for frequencies of possible coexpression patterns across the tissues we queried ( Fig. 3C ), suggesting that a few dominant regulatory paradigms primarily shape the hDRG transcriptome. Out of the top 25 most frequent patterns (5,542 out of the 9,498 tissue-restricted genes in our analysis), 15 correspond to enrichment or de-enrichment in subsets of non-neural tissues, 6 to enrichment in subsets of CNS tissue (Fig. 3D ), and the remaining 4 affecting hDRG expression. The most common co-expression pattern of these was the set expressed pan-neuronally ( Fig. 3E) , the basis of a neuronal gene signature [24] . Previous analyses with hDRG microarray datasets were limited to analyzing a set of predefined probesets, and were unable to identify a broad pan-neuronal transcriptome signature including the hDRG [88; 98] . In our analysis, pan-neuronal genes include splicing factor RBFOX3, ion channels (SCN1A, KCNK1), tyrosine receptor kinase NTRK2, cell adhesion molecule (CAM) gene DOCK3 and the early neural lineage TF SOX1 [82] . The second relevant gene co-expression module consists of genes which are downregulated in the hDRG and spinal cord but expressed in the rest of the CNS (Fig. 3F ), potentially driven by TFs like HOXA3, HOXA4 and HOXB3 involved in rostral-caudal patterning [73] and are common to these two adult human tissues but not more rostral parts of the nervous system. The TF MYT1L is downregulated in hDRG and spinal cord with respect to the rest of the CNS. A third prominent co-expression pattern identifies genes enriched primarily in the CNS but undetectable in the hDRG (Fig. 3G ). These include CNS-expressed genes like SLC32A1 [75] and GLRA2 [122] , known to be suppressed in the DRG, the metabotropic glutamate receptor GRM5 (linked to postsynaptic plasticity in the spinal dorsal horn [36] ), RNA binding protein PABPC1L2A, serotonin 2C receptor HTR2C, and TFs OLIG2 (present in astrocyte and oligodendrocyte cell types, and subpopulations of motor neuron [56] ) and POU3F4. The fourth prominent co-expression pattern was primarily enriched in the hDRG (Fig. 3H) , with the gene set explored in more detail in Section 3.3.
To identify a more comprehensive picture of the regulatory forces driving gene expression in 
hDRG and mDRG enriched genes and a conserved evolutionary signature
Based on the DRG enrichment score, we identified 140 protein coding genes to be hDRGenriched, and 141 protein-coding genes to be mDRG-enriched. Of these 128 hDRG-enriched and 119 mDRG-enriched genes (identified based on Section 2.2, Fig. 5A ) have one-to-one orthologs in the other species. We then looked at the correlation between the human and mouse ortholog uqTPM expression across the analyzed tissue panel to identify if the gene in the other species also had a DRG-enriched expression profile, reported in Table 3 . When we analyzed the distribution of correlation values, we found a large population of highly correlated relative abundance, suggesting that a large fraction of these genes are under negative evolutionary selection in their regulatory regions, causing conserved gene expression profiles across tissues ( Fig. 5B ). 81 out of 128 (63.3%) human genes have correlation scores above 0.68 (the peak in the distribution before the primary mode). All 81 of these genes in both species have the highest relative abundance in DRG across the panel of analyzed tissues, showing a clear conservation of DRG-enrichment. Among the genes we identified with a common pattern of DRG enrichment in mouse and human ( Fig. 5C ), are several that have not been previously studied in DRG biology. These include UCHL1 (neuroepidermal marker of itch [49] ), SKOR2 (a developmental co-repressor in cerebellum [70] ), TRIM67 (shown to be involved in RAS-mediated signaling in the cerebellum [118] ), BET3L (particle transport complex member identified in mDRG single cell studies [51] but not functionally studied), and TLX2 (whose paralog TLX3 is well characterized as a key DRG-enriched TF).
Several DRG-enriched genes show subpopulation restricted expression in the mDRG (expression profiles in mDRG neuronal subpopulations based on Usoskin et al [106] are shown for all DRG-enriched genes in Fig. 5D and Table 4 ), raising the possibility of a similar expression profile in sensory neuronal subpopulations in the hDRG. Among the more well-studied genes are NTRK1, TRPV1, and CALCA (mRNA found in both peptidergic and non-peptidergic neurons), ASIC3
(neurofilament and peptidergic neurons), MRGPRD (non-peptidergic neurons), and PRDM12
(peptidergic, non-peptidergic and TH-positive neurons).
We also identified a gene set which have undetectable gene expression in mDRG scRNA dataset, many of which are known to be expressed in mammalian Schwann cells, detailed in Table 5 .
Known peripheral SGC markers are either weakly expressed in our hDRG datasets (like PAX3 or PAX7) or also expressed in other tissues (like GFAP) and are thus not DRG-enriched. Fibroblast markers like S100A4 are highly expressed in DRG, but are also generically expressed, leading to low DRG-enrichment scores.
We identified that many of the gene products of hDRG-enriched genes can be assigned a handful of molecular roles including transcriptional activators or repressors, receptor and receptor binding, kinases or phosphatases, ion channels, and transmembrane domain containing proteins.
Based on the Enrichr tool [48] , we performed enrichment analysis for biological processes in the Gene Ontology (GO) database [3] (Table 6 ) and molecular pathways in the Reactome database [17] ( Table 7 ) that were enriched in our gene set (Fisher's exact test, p < 0.01 after multiple testing correction). Gene or protein functional ontologies are well known to be incomplete [40] , necessitating us to look at DRG-enriched genes in non-enriched ontology terms and the literature, and showing the diverse roles played by these gene products. Several of these are already well studied in DRG biology. CALCB is a paralog of CALCA with similar function. MRGPR family members are known to play a key role in itch sensation [52] . PIRT is a well-known regulatory subunit of TRPV1 [43] , while PRDM12 is a key TF in neural sensory lineages [12] . Querying the Reactome database (Table 7) yielded enrichment for acetylcholine and nicotinic receptor signaling centered around 3 specific receptor subunits, β3, α6 and α9. The CHRNA6 gene was first identified as a gene potentially involved in mechanical allodynia in mouse, leading to an identification of a novel interaction between α6 nicotinic receptors and P2X3 ion channels that leads to inhibition of P2X3 channel activity [113] .
CHRNA9 (encoding the α9 nicotinic receptor subunit) was recently implicated in development of chemotherapy induced peripheral neuropathic pain using an antagonist of α9 and α10 nicotinic receptors [80] . While more work is needed to validate α9 as the mechanistic target for this compound, the very strong enrichment of CHRNA9 in human DRG makes it an interesting target for this prominent form of neuropathic pain.
More interestingly, we identified many genes whose functional roles in DRG have not been well studied (Fig. 5C ). PPP1R1C, PPM1J, and PPEF1 are phosphatases: PPM1J is known to regulate neurite growth [2] , PPEF1 interacts with Calmodulin in a Ca +2 dependent manner [50] , and DUSP15 regulates the JNK pathway [93] . AMIGO3 [47] is involved in axonal tract development.
SUSD2 is known to regulate neurite growth in hippocampal cultures [68] . TPPP3, PLA2G3, and TRIM36 [97] (along with TUBB3) are associated with the microtubule cytoskeleton. AKAP12 is a kinase scaffold involved in regulating cAMP biosynthesis and signaling. TUSC5 is expressed in the PNS and adipose tissue, and potentially performs shared adipose-nervous system functions [77] .
PTGDR and IL17B are known to be involved in inflammation response, and POLR3G is also involved in cytokine production and immune response. BET3L is part of the TRAPP protein trafficking complex, while NMB is a neuropeptide involved in nociceptive signaling [64] . Additionally, we have a Two previous studies have characterized DRG-enriched genes in humans, but were limited in their scope. Flegel et al [25] analyzed hDRG-enriched genes by chronicling known functionally important gene families in the DRG, and Sapio et al [91] analyzed hDRG-enriched genes from the perspective of sensory neuropathies. In contrast to these, we perform an unbiased, multifaceted enrichment analysis to characterize this gene set. While some of these genes were previously known to be DRG-specific (like TRPV1, MRGPRD, and SCN10A), we identified several genes (like QRFPR) that have not been previously shown to be part of a DRG-enriched transcription regulatory program.
Identifying potential pharmacological targets among tissue-restricted genes in the hDRG
Since a primary goal of our analysis is the identification of potential therapeutics, we performed additional analysis on our DRG-enriched and neurally enriched gene sets to mine for known or new drug targets. We first used our hDRG-enriched gene set to explore the drug -gene product interaction database DGIdb [110] for targets of known drugs (Table 8 ). This identifies genes for which ligand interactions are known, potentially identifying new drugs that can be repurposed or redesigned to target pain. We identified a subset of gene-ligand interactions from DGIdb but these were mostly well-known pain targets with ligands moving into or already in clinical trials. For instance, CALCA (CGRP), P2RX3 (P 2 X 3 ), NTRK1 (TrkA), SCN10A (Nav1.8) and SCN11A (Nav1.9) are all well-known genes involved in pain, most of which have robust ongoing clinical candidate development. Others in this list included nicotinic receptors that were mentioned above but most of the ligands identified lack specificity for these targets. The HTR3A gene, which encodes the 5-HT3 ligand gated ion channel, is enriched in hDRG and many ligands of this receptor subtype are known. Despite a strong case for the role of this receptor in chronic pain states [44] , the pain-relieving potential of antagonists of this receptor have never been clarified in humans, although one small clinical trial in neuropathic pain suggests efficacy of antagonists [57] . Only one gene in this list clearly stood out as novel, QRFPR, which encodes the pyroglutamylated RFamide peptide receptor. This receptor has a known specific ligand but its role in sensory biology and/or pain has not been assessed.
The short list of known ligand to gene interactions identified from the DRG-enriched dataset suggests that many DRG-specific genes have not been explored as drug targets. We thus characterized several pharmacologically important gene families including kinases, phosphatases, ion channels, GPCRs, neuropeptides and associated receptors, and cell adhesion molecules. We also considered that drug targets can include drugs that do not cross the BBB and we therefore included hDRG-expressed genes that had strong neuronal expression but did not show expression in nonneuronal tissues. These genes may be targets for drugs that do not cross the BBB, if DRG targeting is the desired outcome.
Among ion channels, we identified several ion channels with well-known DRG-specific expression (SCN10A, TPRV1, ASIC3 and P2X3) but also identified several others (Fig. 6A ), such as nicotinic receptor subunits α6 and α9 (mentioned above) and potassium channels (KCNK18, KCNS1 and KCNH6). A much larger set of ion channel genes showed enrichment in neuronal tissues with preserved expression in hDRG, and in many cases also in mDRG. Among these were many additional potassium channel genes and strong expression for kainate receptor subtypes, in particular in the hDRG. Several neuropeptide and neuropeptide receptors have been targets of new drugs developed in the past decade [31] . Some candidate drugs targeting these molecules have not been studied due to low bioavailability (because of BBB and other factors) [22] , which is not necessarily a challenge when targeting the DRG. NMB, CALCA, CALCB, and GAL were identified to be hDRGenriched, as was the receptor QRFPR, which was mentioned above. GLRA4, which is a glycine receptor subunit, was expressed in hDRG but not mDRG (Fig. 6B ). Cell Adhesion Molecules (CAMs) are also increasingly viewed as pharmacological targets due to their involvement in processes like inflammation, and cell signaling [45] . We identified several neuronally enriched CAMs like CNTN1, NLGN3, NRCAM, and LRRC4C, but none of these were specific to hDRG (Fig. 6C ). DRG-enriched MPZ and CLDN19 are expressed in Schwann cells, but have gene products that are present at neuron -Schwann cell junctions.
Among GPCRs, the Mas-related GPCR family (including known DRG specific genes in mouse and human) showed DRG enrichment (as expected) as did several other GCPRs including QRFPR, CCKAR and F2RL2 (Fig. 7A ). We also identified several DRG-enriched (OR7E101P, OR51E2) or pan-neurally enriched (OR2L13, OR7A5) olfactory receptors. While we cannot assess if they are enriched in human olfactory epithelium due to a lack transcriptome data for this tissue, we find that the mouse orthologs for OR7A5 and OR51E2 are not expressed in the mouse olfactory epithelium (Sheet 1 of Supplementary File 2) . While the role of olfactory receptors in non-olfactory tissue is under debate, some have been shown to be upregulated in nerve injury models [1] , suggesting that these receptors may have functions outside of their canonical tissue. A broader list of GPCRs were expressed in hDRG and also found in other CNS tissues. Interestingly, these included a large number of orphan GPCRs, suggesting an unmined pharmacological resource for sensory and pain research.
Finally, we assessed kinases ( Fig. 7B ) and phosphatases ( Fig.7C ). Notable among the kinases were NTRK1 and RET, receptor tyrosine kinases for NGF and GDNF, respectively, both of which are wellknown to be DRG-enriched in adult human and mouse. Another weakly enriched receptor tyrosine kinase in hDRG was INSRR, an insulin receptor related receptor. All other kinases we identified were expressed in hDRG but also in other human CNS regions. Several neuron-enriched phosphatases were also detected, including tyrosine phosphatases PTPRN, PTPRN2, and PTPRZ1 but none of these showed a clear enrichment in hDRG.
To delve deeper into identifying DRG enriched genes as putative therapeutic targets, we looked at experimentally validated protein -protein interactions (PPI) in StringDB [26] . We limited this search to interactions within and between the set of DRG-enriched genes and the gene families with drug targeting potential, in a bid to identify pathways with strong therapeutic potential. Based on this network ( Supplementary Fig. 4 ) and intersectional analysis with the KEGG pathway database [42] , we identify several well understood pathways whose components are partially identified, including the neurotrophin signaling, cAMP signaling, retrograde endocannabinoid signaling, and axon guidance pathways. We detailed the neurotrophin signaling pathway (Fig. 8A) , with focus on signaling through the NGF receptor since NGF-targeted therapies are in clinical trials for pain but have an uncertain future due to rare, severe side effects [5] . We find that most gene level abundances for the corresponding proteins in this signaling pathway are present in the hDRG and some are either hDRGenriched (NTRK1, NGFR), or weakly hDRG-enriched (MAPK11, SHC2, ARHGDIA, ARHGDIG, Fig.   8B ). These NGF signaling pathway components may be drug targets to manipulate this pathway in the hDRG with relative specificity.
3.5
Putative axonal localization of mRNAs in hDRG sensory neurons mRNA may be specifically compartmentalized inside somatic or axonal compartments of very long pseudounipolar sensory neurons. Gene expression changes in proximal versus distal portions of peripheral nerves in nerve-injured rats [39] have shown a clear signal of differential gene expression, and abundant evidence links axonally localized mRNAs in mouse DRG neurons to axon growth, regeneration and nociceptive plasticity [41; 59; 60; 63; 114] . Differential gene expression between peripheral nerves and the DRG in humans have only been characterized with respect to peripheral neuropathies [91] , and putative localization of mRNAs to the axons of hDRG neurons has not been examined in general. We contrasted relative abundances of mRNAs in the DRG from our own RNAseq experiments to human tibial nerve RNA-seq experiments from the GTex consortium [16] .
Strikingly, we find fewer than 2,000 genes were detectable in one tissue and not the other, suggesting widespread axonal mRNA transportation (Fig. 9A ).
We found that membrane protein PIRT (regulatory subunit of TRPV1) [43; 101] is localized only to the hDRG with no detectable expression in the hTN. Additionally, we noticed several sensory neuron-specific genes like MAS-related GPCRs MRGPRX1, MRGPRX3, and MRGPRE have downregulated or undetectable gene expression levels in hTN, but are detected at high levels in DRG, suggesting that these mRNAs are not axonally transported. These make them good candidates for neuronal subpopulation level cell body biomarkers for mRNA in situ hybridization studies.
The capacity for injury-induced axonal regeneration and pathfinding is a hallmark of adult PNS neurons [120] . We find several tissue repair associated genes to be more abundant in the hTN with respect to hDRG. The mouse RhoA effector Rock has been shown to be important in regulating axonal pathfinding [115] and to be an axonally targeted mRNA. In hDRGs, ROCK1 and ROCK2 expression were upregulated in hTN suggesting anterograde axonal targeting of mRNA for efficient local translation. Axon guidance receptors NRP1 and NRP2 were similarly more abundant in hTNs with respect to hDRG. Transcription factor protein sequences typically contain NLS sequences that promote retrograde transport to the nucleus. It has thus been hypothesized that anterograde transport of mRNA to axons, stimulus-induced local translation, and retrograde transport of protein to the nucleus is a potential mechanism for growth cone, or nerve ending to nucleus signaling [38] and similar signaling may promote nociceptor sensitization [60] . Several TFs that are known to be involved in axonal regeneration, including TP53, ATF3, FOS, JUN and STAT3 [67] all have higher relative abundance in the hTN over hDRG.
In order to broadly look at genes that were primarily expressed in sensory neurons in the hDRG and hTN, we further limited our analysis to orthologs of genes that are differentially expressed in mDRG neuronal subpopulations ( Fig. 9B and 9C ). Among genes detectable in the hTN, but more abundant in the hDRG, we performed functional enrichment, and identified gene sets corresponding to microtubule binding, ion channel binding, syntaxin binding and tubulin binding (Fig. 9B ). Among genes more abundant in the hTN, suggesting strong axonal transport, we found transmembrane proteins like CRIM1, suggesting that local translation of some proteins may be performed efficiently near their site of action. Additionally we identified SCN5A and NTRK3, members of gene families known to be DRG-enriched, suggesting distinct molecular roles for members of these families in sensory neurons (NTRK1 abundances are enriched in hDRG over hTN) (Fig. 9C) . The relative enrichment of all human genes between the hDRG and hTN nerve is detailed in Sheet 1 of Supplementary File 1.
Discussion
Our analysis profiled the hDRG transcriptome, and contrasted it with other human tissue transcriptomes and their corresponding mouse transcriptomes. By contrasting gene expression patterns across tissues in humans, we created comprehensive gene co-expression modules that take into account gene expression in DRGs. For each co-expression module, we identified putative transcription regulatory genes (TFs, and cofactors). For the co-expression module with genes specifically expressed in the hDRG (and silenced in other analyzed tissues), we identified 13 DRGspecific TFs. We confirmed known mammalian sensory development-related transcription factors in DRG like DRGX, TLX3 and PRDM12 in the adult hDRG, and additionally identified several transcription factors like POU4F1, POU4F3, HOXD1 and SKOR2. We comprehensively catalogued hDRG-expressed members of gene families known to be functionally important in the DRG: ion channels, receptors, kinases, and RNA binding proteins. We note that in the commonly used laboratory mouse strain, C57BL/6, DRG-specific genes are accurately predicted by hDRG-specificity suggesting strong translational capacity for this mouse model. Evolutionary conservation of DRGspecific gene expression suggests purifying selection, and supports the validity of the mouse as a preclinical model species for sensory biology and pain pharmacological and genetic research.
Importantly, our work comprehensively characterized gene expression between hDRG and human tibial nerve, potentially identifying pervasive RNA transport to peripheral axons of hDRG neurons.
There are several factors that distinguish our work from previous studies that used high throughput transcriptome analyses. Our goal was to design an analysis framework to contrast the steady state mRNA profile of different human and mouse tissues, with a focus on identifying gene expression patterns across tissues that can be relevant for understanding DRG biology and guide pain therapeutic discovery. We focused on unbiased gene set enrichment analysis in DRG-specific gene expression patterns for functional analysis, in contrast to Flegel et al [25] who comprehensively characterized expression patterns of gene families known to be important in sensory tissues a priori. [98] . To address these gaps and to generate our own resource for the field, we profiled the mRNA abundances in the hDRG by performing RNA-seq and contrasted it with relevant human and mouse RNA-seq datasets from public repositories, primarily the GTex Consortium [16] . Our quantification is based on a genome-wide readout of transcript abundance not limited to a predefined set of probes, has the added benefit of low technical variability with respect to microarray studies [55] , and unlike the Novartis study is analyzed from the perspective of DRG biology, and drug target discovery in the PNS.
In addition to this, we performed several analyses which characterize the hDRG transcriptome in several biologically relevant ways for the first time. Over and above identifying hDRG-specific genes, gene co-expression analysis across human tissues allowed us to identify gene modules with similar co-expression patterns that are putatively co-regulated, thus taking the first step in identifying the transcriptional regulatory networks underlying fundamental cell types in the hDRG. Identification of hDRG-specific transcription factors allowed us to further identify transcription factors that may be implicated in controlling such regulatory networks into adulthood. Notably, our result divides the wellstudied mammalian pan-CNS expressed genes [18] into CNS genes that are downregulated in the hDRG and those that are expressed in both the CNS and in the hDRG (such as DOCK3, which had been known to be expressed pan-CNS in mouse [71] ).
Based on our comprehensively catalogued and annotated hDRG mRNA profile, we aim to perform several follow up studies. Since we specifically sourced L2 lumbar DRG from female donors, 1
we aim to contrast mRNA profiles between both male and female DRG donors, to identify sex-specific differences in DRG gene expression. We aim to identify if there are region specific differences in the DRG transcriptome by analyzing DRGs from additional spinal levels and that innervate different target tissues. Finally, we aim to perform RNA-seq on cohorts of pain patients to identify both patientspecific and cohort-specific transcriptomic signatures of chronic pain, if they exist, in the hDRG. The absence of these datasets in the present analysis can be viewed as a weakness of this study, but, to our knowledge, these datasets do not exist or are not publicly available. All of our sequencing data is publicly available and can be searched without the need for additional analysis on our resource webpage. This resource can be built upon by interested researchers.
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